Lupus
main-banner
Lupus
C0251013 Enrolling

Research Trial for Lupus – CLE or SLE (65 Weeks)


Treatment: IV Age: 18 Years


Recruiting adults between the ages of 18 and 75 years to take part in this clinical research trial.  Individuals must have a diagnosis of histologically confirmed active cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) with cutaneous manifestations despite treatment with standard of care medications for at least 3 months.  Must not be receiving combinations of 2 or more immunosuppressants.

Participants will receive investigational IV treatment (active study drug) or placebo.  Study treatment and study-related assessments will be provided at no cost.  Reimbursement for study-related expenses may be provided.

Study participation will last about 65 weeks and involve about 16 visits to the study centre.


Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

Dr. Sameh Hanna

Dermatologist

Dr. Wei Jing Loo

Dermatologist

Dr. G. Daniel Schachter

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: June 23, 2024

Official Title

A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF-06823859 IN ADULT PARTICIPANTS WITH ACTIVE CLE OR SLE WITH CUTANEOUS MANIFESTATIONS

ClinicalTrials.gov ID

NCT05879718

Sponsor

Pfizer

Study Description

  • Brief Summary:

    The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms. This study is seeking for participants who: are adults of 18 years of age or older. are confirmed to have CLE or SLE with involvement of the skin. have a Cutaneous Lupus Erythematosus Disease Area and Severity Index activity (CLASI-A) score of at least 8. About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins). At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60. The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period.

  • Condition or Disease:

    Lupus Erythematosus, Systemic

  • Intervention/Treatment:

    Drug: PF-06823859
    Drug: Placebo
  • Phase:

    Phase 2

  • Ages Eligible for Study:

    18 Years and 75 Years (Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

Have a histologically confirmed active CLE or SLE with cutaneous manifestations in the form of subacute cutaneous lupus erythematosus or/and discoid/chronic cutaneous lupus erythematosus at least 3 months and CLASI-A at least 8 or higher.
Participant has adequate intravenous infusion access per investigator’s judgement
Willing to comply with study procedures including skin punch biopsies procedures.
Weight is greater than 40 kg and less than 130 kg.

Exclusion Criteria:

Skin disorders other than CLE or SLE.
Active, severe lupus nephritis requiring treatment with cytotoxic agents or high-dose steroids.
Active severe central nervous system lupus requiring therapeutic intervention within 60 days of baseline.
Cancer or a history of cancer within 5 years of screening except adequately resected basal or squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix.
Known history of a major cardiovascular or cerebrovascular event within 24 months, pulmonary arterial hypertension, pulmonary embolism within 6 months of screening.
Have any autoimmune or inflammatory disease that would interfere with interpretation of test results or clinical assessments.
History of disseminated herpes zoster/simplex or recurrent herpes zoster.
Serious infection within 60 days of baseline or an active infection treated with oral antibiotics within 14 days of baseline.
Have evidence of active or latent infection of hepatitis B or C, known history of human immunodeficient virus (HIV) infection, or infected with Mycobacterium TB (active or latent TB)
Laboratory abnormalities that meet exclusion criteria at the Screening visit. The above information is not intended to contain all considerations relevant to a patient’s potential participation in a clinical trial.


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Lupus

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content